The Burden of the Serious and Difficult-to-Treat Infections and a New Antibiotic Available: Cefiderocol

Activity of Cefiderocol and Comparators against Isolates from Cancer Patients

(2020) Kenneth V.I. Rolston et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Cefiderocol Against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Endemic to Medical Centers in New York City

(2020) Alejandro Iregui et al.   Microbial Drug Resistance

Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia

(2020) Mercedes Delgado-Valverde et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Cefiderocol for extensively-drug resistant gram-negative bacterial infections: real-world experience from a case-series and review of the literature

(2020) Sandra Zingg et al.   Open Forum Infectious Diseases

Case Report: Successful Rescue Therapy of Extensively Drug-Resistant Acinetobacter baumannii Osteomyelitis With Cefiderocol

(2020) Michael Dagher et al.   Open Forum Infectious Diseases

Antibiotic management of urinary tract infection in elderly patients in primary care and its association with bloodstream infections and all cause mortality: population based cohort study

(2019) Myriam Gharbi et al.   BMJ-British Medical Journal

Metabolism, Excretion, and Pharmacokinetics of [14 C]-Cefiderocol (S-649266), a Siderophore Cephalosporin, in Healthy Subjects Following Intravenous Administration

(2019) Shiro Miyazaki et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli

(2019) George G. Zhanel et al.   DRUGS

Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects

(2019) Takayuki Katsube et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Antibiotic Resistance Gene Diversity and Virulence Gene Diversity Are Correlated in Human Gut and Environmental Microbiomes

(2019) Pedro Escudeiro et al.   mSphere

In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models

(2019) Rio Nakamura et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report

(2019) Enrico Maria Trecarichi et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Co-Infections of Two Strains of NDM-1 and OXA-232 Co-producing Klebsiella pneumoniae in a Kidney Transplant Patient

(2019) Deisy A. Contreras et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of Cefiderocol, a Siderophore Cephalosporin, on QT/QTc Interval in Healthy Adult Subjects

(2019) Carlos Sanabria et al.   CLINICAL THERAPEUTICS

Compassionate use of cefiderocol in the treatment of an intraabdominal infection due to multidrug resistant Pseudomonas aeruginosa : A case report

(2019) Ryan W. Stevens et al.   PHARMACOTHERAPY

Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin

(2019) Takafumi Sato et al.   CLINICAL INFECTIOUS DISEASES

In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria

(2019) Yoshinori Yamano   CLINICAL INFECTIOUS DISEASES

LB4. Efficacy and Safety of Cefiderocol vs. High-Dose Meropenem in Patients with Nosocomial Pneumonia—Results of a Phase 3, Randomized, Multicenter, Double-Blind, Non-Inferiority Study

(2019) Richard G Wunderink et al.   Open Forum Infectious Diseases

Long Term Compassionate Use of Cefiderocol to Treat Chronic Osteomyelitis Caused by XDR-Pseudomonas aeruginosa and ESBL-producing Klebsiella pneumoniae in a Pediatric Patient

(2019) Zain I. Alamarat et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

602

(2019) Jana Sigmon et al.   CRITICAL CARE MEDICINE

The impact of law enforcement on dispensing antibiotics without prescription: a multi-methods study from Saudi Arabia

(2019) Alian A. Alrasheedy et al.   Expert Review of Anti-Infective Therapy

Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis

(2018) Nao Kawaguchi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects

(2018) Yutaka Saisho et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters

(2018) Takayuki Katsube et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model

(2018) Islam M. Ghazi et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Trends and Patterns of Differences in Infectious Disease Mortality Among US Counties, 1980-2014

(2018) Charbel el Bcheraoui et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

OUP accepted manuscript

(2018)   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant Pseudomonas aeruginosa

(2018) Islam M. Ghazi et al.   PHARMACOLOGY

Phytochemicals in Helicobacter pylori Infections: What Are We Doing Now?

(2018) Bahare Salehi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Ethnobotany of the genus Taraxacum -Phytochemicals and antimicrobial activity

(2018) Mehdi Sharifi-Rad et al.   PHYTOTHERAPY RESEARCH

Efficacy of Humanized Cefiderocol Exposures Over 72 hours Against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model

(2018) Sean M Stainton et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases

(2018) Michael R. Jacobs et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa

(2018) Jonathan D Edgeworth et al.   CLINICAL INFECTIOUS DISEASES

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015

(2018) James A. Karlowsky et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Stability of cefiderocol against clinically significant broad-spectrum oxacillinases

(2018) Laurent Poirel et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)

(2018) Krystyna M. Kazmierczak et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan

(2018) Shun-Chung Hsueh et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial

(2018) Simon Portsmouth et al.   LANCET INFECTIOUS DISEASES

Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis

(2018) Alessandro Cassini et al.   LANCET INFECTIOUS DISEASES

The cost of antimicrobial resistance

(2018) Ursula Hofer   NATURE REVIEWS MICROBIOLOGY

696. Mechanism of Cefiderocol high MIC mutants obtained in non-clinical FoR studies

(2018) Akinobu Ito et al.   Open Forum Infectious Diseases

Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals

(2017) Matthew E. Falagas et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Staphylococcus aureus colonisation in patients from a primary regional hospital

(2017) Anca Ungureanu et al.   Molecular Medicine Reports

Engineering of obligate intracellular bacteria: progress, challenges and paradigms

(2017) Erin E. McClure et al.   NATURE REVIEWS MICROBIOLOGY

Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial

(2017) Andreas Kronenberg et al.   BMJ-British Medical Journal

Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial

(2017) Andreas Kronenberg et al.   BMJ-British Medical Journal

Clinical and economic impact of antibiotic resistance in developing countries: A systematic review and meta-analysis

(2017) Raspail Carrel Founou et al.   PLoS One

Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity againstPseudomonas aeruginosa

(2016) Akinobu Ito et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases

(2016) Tsukasa Ito-Horiyama et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, for Dose Adjustment Based on Renal Function

(2016) Takayuki Katsube et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A time for action: antimicrobial resistance needs global response

(2016) Tim Jinks et al.   BULLETIN OF THE WORLD HEALTH ORGANIZATION

Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment

(2016) Takayuki Katsube et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Antimicrobial resistance development following surgical site infections

(2016) Daniela Călina et al.   Molecular Medicine Reports

Rare case of disseminated fusariosis in a young patient with graft vs. host disease following an allogeneic transplant

(2016) Alina Tanase et al.   Experimental and Therapeutic Medicine

Treatment outcomes of oral sitafloxacin in acute complicated urinary tract infection and pyelonephritis

(2016) Weerawat Manosuthi et al.   SpringerPlus

Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy

(2015) Aryun Kim et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroAntimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains

(2015) Naoki Kohira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A TRP Channel Senses Lysosome Neutralization by Pathogens to Trigger Their Expulsion

(2015) Yuxuan Miao et al.   CELL

In vitroantimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria

(2015) Akinobu Ito et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Mechanisms of antimicrobial resistance in Gram-negative bacilli

(2015) Étienne Ruppé et al.   Annals of Intensive Care

Investigation of antibacterial effect of Cadmium Oxide nanoparticles on Staphylococcus Aureus bacteria

(2014) Bahareh Salehi et al.   JOURNAL OF NANOBIOTECHNOLOGY

The in vivo extracellular life of facultative intracellular bacterial parasites: Role in pathogenesis

(2012) Manuel T. Silva et al.   IMMUNOBIOLOGY

Combating Antimicrobial Resistance: Policy Recommendations to Save Lives

(2011)   CLINICAL INFECTIOUS DISEASES